NCT03230799

Brief Summary

Previously, we have developed a minimal invasive lens surgery in the purpose of reduce post-operative complications of congenital cataract. This prospective, randomized controlled study aims at comparing the prognosis of the minimal invasive lens surgery and the traditional cataract surgery for treating congenital cataracts.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2017

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 17, 2017

Completed
9 days until next milestone

First Posted

Study publicly available on registry

July 26, 2017

Completed
2 days until next milestone

Study Start

First participant enrolled

July 28, 2017

Completed
4.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2022

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2022

Completed
Last Updated

May 17, 2022

Status Verified

April 1, 2022

Enrollment Period

4.8 years

First QC Date

July 17, 2017

Last Update Submit

May 10, 2022

Conditions

Keywords

congenital cataractminimal invasive surgerysecondary intraocular lens implantation

Outcome Measures

Primary Outcomes (1)

  • Best correctied visual acuity

    Determined with the Teller's acuity card, the Lea symbol visual acuity chart or the ETDRS chart according the patient's age.

    recorded at each follow-up to five years of age.

Secondary Outcomes (3)

  • High intra-ocular pressure

    after lens removal to five years of age.

  • Visual axis opacification

    after lens removal to five years of age.

  • Bi-ocular visual function

    performed when the patient is four years old and five years old.

Study Arms (2)

traditional cataract surgery

ACTIVE COMPARATOR

Central anterior continuous capsulorhexis (5-6 mm)+ irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy(ACCC+ I/A + PCCC + Anti-vit)

Procedure: traditional cataract surgery

minimal invasive lens surgery

EXPERIMENTAL

Peripheral capsulorhexis opening (1.0-1.5 mm)+irrigation/aspiration

Procedure: minimal invasive lens surgery

Interventions

We decreased the size of the capsulorhexis opening to 1.0-1.5 mm in diameter. Then we moved the location of the capsulorhexis to the peripheral area of the lens instead of the central area. A 0.9 mm phacoemulsification probe was used to remove the lens contents and/or cortical opacities.

minimal invasive lens surgery

ACCC+ I/A + PCCC + Anti-vit: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy

traditional cataract surgery

Eligibility Criteria

Age1 Month - 24 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Age between 1 month and 24 months
  • Uncomplicated congenital cataract (≥ 3 mm central dense opacity) in one or both eyes with an intact non-fibrotic capsular bag
  • Informed consent signed by a parent or legal guardian

You may not qualify if:

  • confirmed or suspected hereditary cataract, including and not restricted to family history of congenital cataract
  • Intraocular pressure \>21 mmHg
  • Preterm birth (\<28 weeks)
  • Presence of other ocular diseases (keratitis, keratoleukoma, aniridia, glaucoma) or systemic disease (congenital heart disease, ischemic encephalopathy)
  • History of ocular diseases (any congenital eye diseases, such as, congenital cataract, congenital glaucoma, congenital aniridia) in the family
  • History of ocular trauma
  • Microcornea
  • Persistent hyperplastic primary vitreous
  • Rubella
  • Lowe syndrome

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Zhongshan Ophthalmic Center,Sun Yat-sen U

Guangzhou, Guangdong, 510060, China

RECRUITING

Study Officials

  • Yizhi Liu, M.D,Ph.D

    Zhongshan Ophthalmic Center, Sun Yat-sen University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Professor

Study Record Dates

First Submitted

July 17, 2017

First Posted

July 26, 2017

Study Start

July 28, 2017

Primary Completion

June 1, 2022

Study Completion

December 1, 2022

Last Updated

May 17, 2022

Record last verified: 2022-04

Data Sharing

IPD Sharing
Will not share

Locations